The HTT Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population engineered for loss-of-function studies of the huntingtin (HTT) gene. This product delivers a heterogeneous pool of edited cells, each carrying CRISPR-mediated disruption at the target locus, enabling robust assessment of gene function without clonal selection biases. The HTT gene encodes huntingtin, a large scaffold protein implicated in vesicular trafficking, transcriptional control, and apoptosis regulation. By ablating HTT expression across the cell pool, researchers can interrogate the protein??s role in autophagy, endocytosis, and neurotrophin signaling pathways.
Host cell background: The HeLa cell line is derived from a cervical adenocarcinoma and is among the most widely utilized human cell lines in biomedical research. These cells are HPV18-positive, with viral oncoproteins E6 and E7 inactivating the tumor suppressors p53 and pRb, respectively, while telomerase activity maintains proliferative capacity. This immortalized phenotype ensures stable, scalable culture conditions. The polyclonal knockout population is generated in a HeLa background, retaining these well-characterized genetic and epigenetic features, thereby providing a consistent experimental platform for HTT functional analysis.
Molecularly, huntingtin operates as a scaffold coordinating multiprotein complexes. It is regulated by transcription factors such as CREB1, NFKB1, and SP1, and it interacts with partners including HAP1, HIP1, HIP14, GAPDH, and PACSIN1. Downstream, HTT influences the expression and activity of BDNF, caspase-3, and BAX, thereby modulating neuronal survival and apoptotic cascades. In the HeLa knockout model, loss of huntingtin disrupts the HTT-HAP1-caspase-3-BDNF signaling axis, impairing vesicular transport and altering autophagic flux. This disruption sensitizes cells to stress-induced apoptosis, offering a tractable system to study the molecular pathology of Huntington??s disease.
The absence of huntingtin in HeLa cells provides unique insights into non-neuronal functions of HTT. Since HeLa cells lack neuron-specific pathways, the knockout phenotype highlights cell-type-independent roles of huntingtin in fundamental processes like endocytosis and transcriptional regulation. The model enables dissection of HTT??s contribution to cancer-relevant signaling, given the role of p53 and Rb inactivation in HeLa cells. Researchers can examine how HTT loss influences proliferation, survival, and response to chemotherapeutic agents, complementing studies in neuronal models. This polyclonal format preserves biological variability, making it suitable for robust, reproducible investigations.
Typical applications include mechanistic studies of Huntington??s disease, drug screening for neuroprotective compounds, and evaluation of HTT-dependent apoptosis and autophagy. Users can validate knockout via Western blot or RT-qPCR, localize residual huntingtin by immunofluorescence, and quantify functional readouts such as caspase-3 activity or autophagy flux measurements. The polyclonal population is well-suited for high-throughput viability assays and signaling studies under perturbed conditions. For additional product details and technical support, please contact Ascent Research.
